Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
454
datasets available to search
ShareScore release 0.9.0
Dataset results
454 results for “Tamoxifen”
Effects of Tamoxifen on the Reproductive System of Females with Breast Cancer
<p><strong>Background: </strong>Tamoxifen (TMX) currently regarded as the standard treatment for breast cancer (BC) patients‎, however in recent years, several researchers reported gynecological side effects and attributed them to TMX and its estrogenic (ER) effects. We evaluate the side effects of TMX on female ‎endometrium and ovaries.</p> <p><strong>Methods:</strong> an ultrasound-based cohort study conducted in three oncology centers. The studied groups included a total of ‎‎255 patients, 140 premenopausal (PreM) and 115 postmenopausal (PostM) female patients with ER-positive BC using TMX adjuvant hormonal treatment in ‎a dose of 20 mg/day for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ The study conducted at the three main oncology centers in Baghdad. The collected data includes: age of the patient, menopausal status, co-morbid chronic illness such as hypertension, diabetes mellitus, etc, and used medications.</p>
Effects of Tamoxifen on the Reproductive System of Females with Breast Cancer – an Ultrasound-based Cohort study
<p>This data represent an ultrasound-based cohort study conducted in three oncology centers. The studied groups included a total of ‎‎255 patients, 140 premenopausal (PreM) and 115 postmenopausal (PostM) female patients with ER-positive BC using TMX adjuvant hormonal treatment in ‎a dose of 20 mg/day for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ The study conducted at the three main oncology centers in Baghdad. The collected data includes: age of the patient, menopausal status, co-morbid chronic illness such as hypertension, diabetes mellitus, etc, and used medications.an ultrasound-based cohort study conducted in three oncology centers. The studied groups included a total of ‎‎255 patients, 140 premenopausal (PreM) and 115 postmenopausal (PostM) female patients with ER-positive BC using TMX adjuvant hormonal treatment in ‎a dose of 20 mg/day for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ The study conducted at the three main oncology centers in Baghdad. The collected data includes: age of the patient, menopausal status, co-morbid chronic illness such as hypertension, diabetes mellitus, etc, and used medications.</p>
Refined tamoxifen administration in mice by encouraging voluntary consumption of palatable formulations.
<p>Drug administration in preclinical rodent models is essential for research and the development of novel therapies. Compassionate administration methods have been developed, but these are mostly incompatible with water-insoluble drugs such as <span>tamoxifen</span> <span>or</span> do not <span>allow for</span> precise timing or dosing of the drugs. <span>For more than two decades, tamoxifen has been administered by oral gavage or injection to </span>CreER<sup>T2</sup>/loxP gene-modified mouse models<span> </span>to <span>spatiotemporally control gene expression,</span><span> with the numbers of such inducible models </span><span>steadily increasing in recent years. </span>Animal-friendly procedures <span>for</span> accurately administering <span>tamoxifen or </span><span>other water-insoluble </span><span>drugs </span>would, therefore, have an important impact on animal <span>welfare.</span> <span>Based on a previously published micropipette feeding protocol, we developed palatable formulations to encourage voluntary consumption of tamoxifen. We </span><span>evaluated</span><span> </span><span>the acceptance of the new formulations by mice during training and treatment and assessed the efficacy of </span><span>tamoxifen-mediated induction of </span>CreER<sup>T2</sup>/loxP-dependent reporter <span>gene</span><span>s</span><span>.</span> <span>Both sweetened </span><span>milk</span><span> and syrup-based formulations encouraged mice to consume tamoxifen voluntarily, but only sweetened milk formulations were statistically </span><span>non-inferior</span><span> to oral </span><span>gavage or intraperitoneal injections in inducing </span><span>CreER<sup>T2</sup>-mediated</span><span> gene expression. </span><span><span>Serum concentrations of tamoxifen metabolites, quantified using an in-house developed cell assay, confirmed the lower efficacy of syrup- as compared to sweetened milk-based formulations.</span></span> We found dosing with a micropipette to be more accurate than oral gavage or injection, with the added advantage that the method requires little training for the experimenter. <span>The new palatable solutions encourage voluntary consumption of tamoxifen without loss of </span><span>efficacy</span><span> compared to oral gavage or injections and </span><span>thus represent</span><span> </span>a refined administration method.</p>
Transcriptomic profiles of MCF7-derived tamoxifen resistant cell lines
<p>We report mRNA profiles of human breast cancer cell lines, MCF7 parental, and MCF7-derived tamoxifen-resistant cell lines MCF7-TR1 and MCF7-TR2.</p> <p>These cells have been previously described in </p> <p>Ines Barone, Lauren Brusco, Guowei Gu, Jennifer Selever, Amanda Beyer, Kyle R. Covington, Anna Tsimelzon, Tao Wang, Susan G. Hilsenbeck, Gary C. Chamness, Sebastiano Andò, and Suzanne A.W. Fuqua. Loss of Rho GDIα and Resistance to Tamoxifen via Effects on Estrogen Receptor α. J Natl Cancer Inst. 2011 Apr 6; 103(7): 538–552. PMID: 21447808</p>
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
ClinicalTrials.gov study NCT00601900. IPD Sharing: Not stated. Countries: 2. Publications: 4.
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
ClinicalTrials.gov study NCT00108069. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
ClinicalTrials.gov study NCT00295646. IPD Sharing: NO. Countries: 2. Publications: 16.
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
ClinicalTrials.gov study NCT00072462. IPD Sharing: Not stated. Countries: 14. Publications: 3.
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
ClinicalTrials.gov study NCT02093351. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Impact of Low-dose Tamoxifen on BPU
ClinicalTrials.gov study NCT02979301. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjec
ClinicalTrials.gov study NCT01189500. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
ClinicalTrials.gov study NCT00710970. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
ClinicalTrials.gov study NCT00756717. IPD Sharing: NO. Countries: 1. Publications: 1.
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
ClinicalTrials.gov study NCT00066690. IPD Sharing: Not stated. Countries: 3. Publications: 13.
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
ClinicalTrials.gov study NCT02993159. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
ClinicalTrials.gov study NCT01124695. IPD Sharing: YES. Countries: 3. Publications: 1.
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
ClinicalTrials.gov study NCT00659373. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
ClinicalTrials.gov study NCT01272037. IPD Sharing: Not stated. Countries: 10. Publications: 3.
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
ClinicalTrials.gov study NCT02747004. IPD Sharing: YES. Countries: 14. Publications: 1.
Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)
ClinicalTrials.gov study NCT02824224. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.